AQST241115C5000
- 0.70
- -0.16-18.60%
Aquestive Therapeutics Newsroom
Leerink Partners Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Raises Target Price to $13
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $7
A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $7 to $10
Aquestive Therapeutics Analyst Ratings
Strong Buy Rating for Aquestive Therapeutics' Anaphylm Driven by Promising Study Results and Market Potential
Lake Street Remains a Buy on Aquestive Therapeutics (AQST)
Leerink Partners Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $12
Aquestive Therapeutics: A Buy Rating on Revolutionary Allergy Treatments and Strategic Pipeline Expansion
Aquestive Therapeutics Analyst Ratings
JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Aquestive Therapeutics (AQST) and Inspire Medical Systems (INSP)
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $7
Leerink Partners Reiterates Outperform on Aquestive Therapeutics, Raises Price Target to $12
Aquestive Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Aquestive Therapeutics Analyst Ratings
H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Raises Target Price to $10
JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Aquestive Therapeutics: A Buy Rating on Underappreciated Market Potential and Innovative Pipeline
Aquestive Therapeutics Analyst Ratings
Buy Rating Affirmed for Aquestive Therapeutics as Anaphylm Poised to Transform Epinephrine Market